Plasma Protein Therapeutics Association

What Plasma Protein Therapeutics Association does

Plasma Protein Therapeutics Association (PPTA) is a private nonprofit trade association founded in 1992 that represents the manufacturers of plasma-derived and recombinant therapies worldwide. Headquartered in the Washington, D.C. area (Annapolis mailing address, D.C. contact line), PPTA operates with 11–50 employees and serves a global membership spanning plasma collection centers (~1,200 in the United States alone) and the major fractionators of the industry — including Takeda, Kedrion, Grifols, ADMA Biocenters, Kamada, BioLife, ABO Plasma, Previpharma, and Unica Plasma. The association's mission is to protect plasma donors and ensure patient access to safe, effective plasma-derived medicines used to treat rare and chronic conditions such as primary immunodeficiencies, hemophilia, alpha-1 antitrypsin deficiency, and hereditary angioedema.

PPTA's core "products" are a portfolio of industry programs rather than commercial goods. These include certification and standards programs — the International Quality Plasma Program (IQPP) for plasma collection centers and Quality Standards of Excellence, Assurance and Leadership (QSEAL) for manufacturers — and safety/communication infrastructure such as the National Donor Deferral Registry (NDDR), the Patient Notification System (PNS), and the North America Data Program. The association also convenes the global plasma community through flagship events (International Plasma Protein Congress, Plasma Protein Forum), runs the annual International Plasma Awareness Week (IPAW) campaign, publishes The Source Magazine quarterly, and hosts webinars and a multimedia content library. It maintains an active regulatory and policy engagement footprint with the FDA, EMA, European Commission, European Parliament, and national health ministries.

PPTA's business model is membership-fee based. Revenue is generated through membership dues paid by collection centers and manufacturers; PPTA does not sell plasma-derived products and does not set prices for them. Member benefits include regulatory advocacy, crisis management assistance, industry data and briefings, publications, and conference discounts. The association operates a multilingual digital presence (English, Spanish, Italian, Hungarian, Czech, German, French) reflecting its global reach, and derives strategic influence from regulatory wins such as the German Bundestag's exemption of blood plasma products from an additional 8.5% manufacturer discount under the GKV Contribution Rate Stabilization Act.

Name

Plasma Protein Therapeutics Association

Legal name

Plasma Protein Therapeutics Association

Website

https://pptaglobal.org

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

The Plasma Protein Therapeutics Association (PPTA) is a nonprofit trade association founded in 1992 that represents global manufacturers and collectors of plasma-derived therapies. It sets industry standards, operates donor safety databases, convenes annual congresses, and advocates with regulators on behalf of members including Takeda, Kedrion, and Grifols.

Ownership category

akta.pro rank

Product category

Pharmaceutical Industry Trade Association

NAICS

Blood and Organ Banks (621991)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Public–Private Partnerships (PPPs) for Global Health (HLAJAOAD)

Keywords

• Plasma protein therapeutics
• Trade association advocacy
• Plasma collection standards
• Regulatory affairs consulting
• Donor safety programs

Headquarters

HQ city

Annapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Membership Dues: PPTA generates revenue through membership dues paid by plasma collection centers and manufacturers. As stated on the website: 'By being a member of our industry-leading association, you can work closely with influential partners, enjoy numerous benefits and access useful resources.' Membership benefits include 24-hour crisis management assistance, subscriptions to industry briefings, magazine and reports, and discounts for two premier annual industry conferences.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels11 records

Core offering

PPTA is a trade association that represents the manufacturers of plasma-derived and recombinant therapies and their network of plasma collection centers. Its core offering consists of industry advocacy with global regulators (FDA, EMA, EU Parliament), member certification and quality standards programs (IQPP, QSEAL), donor and patient safety infrastructure (NDDR, Patient Notification System, North America Data Program), and industry convening events (International Plasma Protein Congress, Plasma Protein Forum, International Plasma Awareness Week). Membership dues from plasma collection centers and manufacturers fund these services.

Product overview

PPTA is a trade association representing the plasma protein therapeutics industry. Rather than offering a unified software product, PPTA provides a portfolio of standards programs, safety databases, and plasma therapies. The core standards programs include IQPP (certification for plasma collection centers) and QSEAL (manufacturing quality standards). Safety infrastructure includes the NDDR (donor deferral database) and Patient Notification System. PPTA also facilitates plasma therapies knowledge including immunoglobulins, clotting factors, albumin, and specialty proteins. Member services include the PPTA Portal, The Source Magazine publication, and educational video content. The association organizes major annual events including the International Plasma Protein Congress (IPPC) and Plasma Protein Forum, and runs the International Plasma Awareness Week (IPAW) campaign.

Differentiator

Problem solved

Functional benefit

Brands

• International Plasma Awareness Week (IPAW): Annual awareness week dedicated to celebrating plasma donors and raising awareness about plasma-derived medicines and plasma donation.

Products and services

• International Quality Plasma Program (IQPP) A voluntary certification program for plasma collection centers establishing industry standards for quality and safety in plasma sourcing for fractionation. Used by member collection centers worldwide to demonstrate compliance with PPTA's quality standards to regulators and partners.
• Quality Standards of Excellence, Assurance and Leadership (QSEAL) A quality standards certification program for plasma protein therapy manufacturers, setting excellence, assurance, and leadership benchmarks for production and safety. Used by member manufacturers to demonstrate manufacturing quality.
• National Donor Deferral Registry (NDDR) A database service that tracks permanently deferred plasma donors in North America. Donors who test reactive for HIV, HBV, and HCV are added to the registry and prohibited from donating at licensed collection centers in the U.S. and Canada, supporting safety of plasma-derived therapies.
• Patient Notification System (PNS) A free, confidential, 24-hour communication service that notifies patients and registrants about withdrawals and recalls of plasma protein therapies via email, telephone, text messaging, or fax. Operated by PPTA for the patient community.
• PPTA Portal A web-based member portal hosted on SharePoint for registered users with PPTA management or governance roles, providing access to association resources, tools, and collaboration features.
• The Source Magazine PPTA's official quarterly magazine covering plasma industry news, patient stories, regulatory updates, and association activities. Provided as a member benefit in Spring, Summer, Fall, and Winter editions.
• International Plasma Protein Congress (IPPC) An annual premier congress convening global plasma industry leaders, regulators, and experts for keynote sessions, networking, and collaboration on plasma protein therapeutics. Held in major international cities (Warsaw 2025, Milan 2026).
• Plasma Protein Forum Annual industry forum focused on plasma protein therapeutics issues, policy developments, and business strategy for the plasma protein therapeutics industry. Includes the annual Congressional Fly-In on Capitol Hill. The 2025 edition was titled 'Taking Steps Toward a Better Tomorrow.'
• International Plasma Awareness Week (IPAW) An annual global awareness campaign (held October 6-10) celebrating plasma donors and raising awareness about plasma donation and plasma-derived medicines. Includes the Global Patient Survey, social media activations, and free resources for members and patient organizations.
• North America Data Program A web-based data distribution program providing comprehensive monthly distribution data for plasma protein therapies across North America, supporting transparency and supply chain visibility for member companies.

Quantifiable outcome

• PPTA's advocacy contributed to the German Bundestag exempting supply-critical blood plasma products from an additional 8.5% manufacturer discount in the GKV Contribution Rate Stabilization Act
• +1 more outcomes

Named customers9 records

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

14 partnerships are on record, tiered core and minor.

• AIP (Associazione Immunodeficienze Primitive)coreStrategic or Co-development Partner · 28 April 2026PPTA awarded a grant to AIP (Italy's primary immunodeficiency patient organization) to advance patient advocacy and awareness in Italy. This partnership supports AIP's work in representing patients who rely on plasma-derived medicines, aligning with PPTA's mission to ensure patient access to plasma therapies.
• EPA (European Plasma Alliance)coreStrategic or Co-development Partner · 30 January 2026PPTA and EPA jointly welcomed the Hungarian Donor Registry, collaborating on advocacy for donor safety and plasma supply across Europe. This partnership reflects ongoing EPAPPTA cooperation on European plasma policy.
• TakedacoreStrategic or Co-development PartnerTakeda is a key member company of PPTA, participating in association governance, events, and standards programs. Takeda's representatives serve on PPTA's Global Executive Board and European Board leadership. Takeda is one of the world's largest plasma-derived therapy manufacturers.
• KedrioncoreStrategic or Co-development PartnerKedrion is a member of PPTA and participates in association governance, industry events, and regulatory advocacy. Kedrion's representatives have been interviewed at PPTA's Plasma Protein Forum and contributed to industry discussions on plasma supply and safety.
• GrifolscoreStrategic or Co-development PartnerGrifols is a member company of PPTA and participates in association events and programs. Grifols' representatives have been interviewed at PPTA forums and the company operates plasma collection centers. Grifols Egypt CEO was interviewed by PPTA's President and CEO.
• KamadacoreStrategic or Co-development PartnerKamada is a member of PPTA. Representatives including Lemon Williams II (US Plasma Quality Director) and Steve Mitzelfelt (U.S. Regulatory Affairs Director) have been interviewed at PPTA's 2025 Plasma Protein Forum.
• FDA (U.S. Food and Drug Administration)coreOthersPPTA maintains an ongoing regulatory liaison with the FDA, holding annual liaison meetings (most recently November 8, 2023). PPTA submits comments on FDA guidance documents and provides industry perspectives on regulatory policy affecting plasma-derived medicines.
• EMA (European Medicines Agency)coreOthersPPTA engages with EMA on regulatory matters affecting plasma-derived medicines in Europe. PPTA has responded to EMA regulatory updates on topics such as variant Creutzfeldt-Jakob Disease (vCJD) and has provided input on EU regulatory frameworks.
• European Parliament / European CommissioncoreOthersPPTA actively engages with European Parliament and Commission on key regulatory files including the SoHO Regulation, Critical Medicines Act, and EU Pharmaceutical Legislation revision. PPTA submitted responses to the Council's negotiating mandate on SoHO Regulation and advocated on plasma collection policy during EU BTC revision discussions.
• Allo Hope FoundationminorGTM or Marketing PartnerKatie Shanahan, Director of Development at Allo Hope Foundation, was interviewed at PPTA's 2025 Plasma Protein Forum, representing a patient organization perspective at the association's industry event.
• Jeffrey Modell FoundationminorGTM or Marketing PartnerVicki and Fred Modell, Co-Founders of the Jeffrey Modell Foundation, were featured in Episode 4 of PPTA's 'Plasma is Life' podcast series, discussing primary immunodeficiency and the importance of plasma donation.
• GBS|CIDP FoundationminorGTM or Marketing PartnerNancy Di Salvo from the GBS|CIDP Foundation was featured in Episode 5 of PPTA's 'Plasma is Life' podcast series, discussing Guillain-Barré Syndrome and related conditions treated with plasma-derived immunoglobulins.
• Columbia University (Medical Research)minorOthersDr. Steven L. Spitalnik from Columbia University was interviewed at PPTA's 2025 Plasma Protein Forum, contributing medical and scientific expertise to the association's industry discussions.
• PPTA Deutschland / PPTA EuropecoreOthersPPTA's European division (PPTA Europe) engages with EU institutions on regulatory policy. PPTA Deutschland welcomed the GKV Contribution Rate Stabilization Act exemption for blood plasma products in Germany (July 2026), demonstrating advocacy impact at national level within the EU.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Biotechnology Innovation Organization (BIO): BIO is the largest U.S. trade association representing the biotechnology industry, including biopharmaceutical manufacturers. PPTA is comparable as a similarly structured advocacy organization, but BIO operates at a broader industry level while PPTA focuses specifically on plasma protein therapeutics manufacturers.
• PhRMA (Pharmaceutical Research and Manufacturers of America): PhRMA represents major U.S. pharmaceutical manufacturers and engages in regulatory advocacy, policy influence, and standards-setting. PPTA is comparable as a pharma trade association with similar advocacy and regulatory engagement, though PhRMA covers a broader pharmaceutical industry beyond plasma-derived therapies.

Direct peers

• AABB (formerly American Association of Blood Banks): AABB is an international association focused on transfusion medicine and cellular therapies, including standards for blood and plasma collection. PPTA is a direct peer in the standards-setting and donor safety space, with overlapping membership in plasma collection centers and similar regulatory engagement with FDA.
• America's Blood Centers: America's Blood Centers is a North American association of independent community blood centers. PPTA is directly comparable as a blood/plasma industry trade association focused on donor supply, though PPTA concentrates on plasma-derived therapy manufacturers rather than whole blood banking.
• International Plasma Fractionation Association (IPFA): IPFA is a global organization focused on plasma fractionation science, manufacturing, and supply. PPTA is directly comparable as a global plasma industry association, with closely overlapping membership in plasma fractionators and shared focus on plasma supply, safety, and regulatory issues.
• European Plasma Alliance (EPA): EPA is a European association of plasma collectors and fractionators. PPTA is directly comparable as a peer plasma industry association; in fact, PPTA and EPA jointly welcomed the Hungarian Donor Registry, illustrating overlapping advocacy and mutual recognition of roles.

Regional players

• European Blood Alliance (EBA): EBA is a European association of blood establishments. PPTA is comparable as a regional peer in blood/plasma supply chain advocacy, with overlapping member interests in donor safety and supply regulation, though EBA primarily serves the European whole blood and plasma collection sector.
• Plasma Protein Therapeutics Australia (PPTA Australia): PPTA Australia is a regional affiliate of the global PPTA network focused on plasma supply and access in Australia. PPTA is directly comparable as a sister association under the broader PPTA umbrella, with shared mission and overlapping member companies, though the regional entity focuses on Australian regulatory and supply issues.

Emerging players

• National Hemophilia Foundation (NHF): NHF is a U.S. patient advocacy organization for people with bleeding disorders who depend on plasma-derived clotting factors. PPTA is comparable as a stakeholder in the plasma-derived therapy ecosystem, with overlapping interests in patient access and supply, though NHF focuses on patient advocacy rather than industry representation.
• Immune Deficiency Foundation (IDF): IDF is a U.S. patient advocacy organization for people with primary immunodeficiency diseases who rely on immunoglobulin replacement therapies. PPTA is comparable as a stakeholder in plasma-derived therapy access, with shared interest in supply security and patient advocacy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/PPTAEurope
• Facebookfacebook.com/PPTAEurope
• LinkedInlinkedin.com/company/plasma-protein-therapeutics-association
• Instagraminstagram.com/pptaglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Plasma Protein Therapeutics Association